Physician profile
Rajesh Rethnam
NPI 1275634289
$3,415.30
in general payments reported to CMS, 2019-2025
32 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what 80% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $40.13 · 2021: $150 · 2022: $337 · 2023: $470 · 2024: $805 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,409 · Education: $91.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,409.06 |
| Education | $91.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $708.79 | 2021-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $326.71 | 2021-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Philips North America LLC | $267.34 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und, Incourage Airway Clearance Therapy |
| Mylan Specialty L.P. | $252.87 | 2019-2024 | Yupelri |
| Viatris Specialty LLC | $195.85 | 2025 | Yupelri |
| Harmony Biosciences LLC | $146.05 | 2024-2025 | |
| Amgen INC. | $138.43 | 2022-2025 | Tezspire, Repatha, Repatha |
| Inspire Medical Systems, INC. | $136.41 | 2023-2025 | Inspire |
| Genentech USA, INC. | $128.94 | 2019 | |
| Electromed, INC. | $126.67 | 2021-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.61 | 2019-2025 | Ofev, Jascayd |
| Verona Pharma, INC. | $94.55 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $91.69 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Intuitive Surgical, INC. | $76.92 | 2025 | |
| Lilly USA, LLC | $72.48 | 2023-2025 | Mounjaro, Zepbound |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $57.67 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $56.57 | 2025 | Lumryz |
| Itamar Medical INC | $47.32 | 2023-2024 | Watchpatone |
| Jazz Pharmaceuticals INC. | $46.68 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $33.01 | 2021 | |
| Novo Nordisk INC | $32.90 | 2023 | Ozempic, Rybelsus, Tresiba |
| Inogen, INC. | $31.45 | 2025 | |
| Resmed Corp | $30.47 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $28.66 | 2024 | Dupixent |
| Axsome Therapeutics, INC. | $27.64 | 2024 | Sunosi |
| Grifols USA, LLC | $26.47 | 2025 | Prolastin-C Liquid |
| Shionogi INC | $26.40 | 2024 | Fetroja |
| Sunovion Pharmaceuticals INC. | $22.88 | 2019 | |
| Abbott Laboratories | $22.63 | 2025 | Freestyle Libre 3 |
| Tactile Systems Technology INC | $18.83 | 2024 | Flexitouch Plus, Entre Plus |
| Advanced Respiratory, INC | $18.16 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.25 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Rethnam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.